tetano
Editor, Senior Moderator
Vaccine. 2010 Dec 22. [Epub ahead of print]
Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, S?kaly RP, Boivin G.
Centre de Recherche du Centre Hospitalier de l'Universit? de Montr?al, Montr?al, Qc, Canada; D?partement de Microbiologie et Immunologie, Universit? de Montr?al, Montr?al, Qc, Canada.
Abstract
We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p=0.539) or HIV viral load (p=0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.
Copyright ? 2010. Published by Elsevier Ltd.
PMID: 21185423 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21185423
Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, S?kaly RP, Boivin G.
Centre de Recherche du Centre Hospitalier de l'Universit? de Montr?al, Montr?al, Qc, Canada; D?partement de Microbiologie et Immunologie, Universit? de Montr?al, Montr?al, Qc, Canada.
Abstract
We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p=0.539) or HIV viral load (p=0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.
Copyright ? 2010. Published by Elsevier Ltd.
PMID: 21185423 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21185423